Log in

NASDAQ:CGENCompugen Stock Price, Forecast & News

$14.31
+0.39 (+2.80 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.80
Now: $14.31
$14.38
50-Day Range
$7.45
MA: $12.83
$15.58
52-Week Range
$2.73
Now: $14.31
$16.31
Volume676,114 shs
Average Volume1.05 million shs
Market Capitalization$979.09 million
P/E RatioN/A
Dividend YieldN/A
Beta2.87
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Read More
Compugen logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.80 million
Book Value$0.75 per share

Profitability

Net Income$-27,340,000.00

Miscellaneous

Employees89
Market Cap$979.09 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Compugen (NASDAQ:CGEN) Frequently Asked Questions

How has Compugen's stock been impacted by COVID-19 (Coronavirus)?

Compugen's stock was trading at $11.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CGEN stock has increased by 21.0% and is now trading at $14.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Compugen?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Compugen.

When is Compugen's next earnings date?

Compugen is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Compugen.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.10). During the same quarter in the prior year, the firm earned ($0.14) EPS. View Compugen's earnings history.

What price target have analysts set for CGEN?

6 analysts have issued 12-month price objectives for Compugen's stock. Their forecasts range from $13.00 to $28.00. On average, they anticipate Compugen's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price. View analysts' price targets for Compugen.

Has Compugen been receiving favorable news coverage?

News stories about CGEN stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Compugen earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutCompugen.

Who are some of Compugen's key competitors?

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Gilead Sciences (GILD), Novavax (NVAX), Pluristem Therapeutics (PSTI), Inovio Pharmaceuticals (INO), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Alibaba Group (BABA).

Who are Compugen's key executives?

Compugen's management team includes the following people:
  • Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
  • Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
  • Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
  • Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
  • Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Who are Compugen's major shareholders?

Compugen's stock is owned by a number of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (12.22%), Nikko Asset Management Americas Inc. (12.22%), RA Capital Management L.P. (4.32%), Morgan Stanley (1.27%), Taylor Frigon Capital Management LLC (0.92%) and DAFNA Capital Management LLC (0.88%).

Which major investors are selling Compugen stock?

CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Taylor Frigon Capital Management LLC, Morgan Stanley, Jane Street Group LLC, UBS Group AG, BlackRock Inc., Private Advisor Group LLC, and Citigroup Inc..

Which major investors are buying Compugen stock?

CGEN stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management L.P., DAFNA Capital Management LLC, Sofinnova Investments Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Phoenix Holdings Ltd., Mackenzie Financial Corp, and Advisor Group Holdings Inc..

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $14.31.

How big of a company is Compugen?

Compugen has a market capitalization of $979.09 million and generates $17.80 million in revenue each year. The biotechnology company earns $-27,340,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Compugen employs 89 workers across the globe.

What is Compugen's official website?

The official website for Compugen is www.cgen.com.

How can I contact Compugen?

Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.